Anders G Holst

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4954083/publications.pdf

Version: 2024-02-01

88 10,200 42 87
papers citations h-index g-index

90 90 90 12396
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Fascicular heart blocks and risk of adverse cardiovascular outcomes: Results from a large primary care population. Heart Rhythm, 2022, 19, 252-259.	0.3	8
2	Associations between primary care electrocardiography and non-Alzheimer dementia. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106640.	0.7	1
3	Early glycaemic changes after initiation of oral antidiabetic medication and risk of major adverse cardiovascular events: results from a large primary care population of patients with type 2 diabetes. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 486-495.	1.4	3
4	Electrocardiographic T-wave morphology and risk of mortality. International Journal of Cardiology, 2021, 328, 199-205.	0.8	9
5	Comparison of the three-level and the five-level versions of the EQ-5D. European Journal of Health Economics, 2021, 22, 621-628.	1.4	13
6	Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet, The, 2021, 398, 1507-1516.	6.3	251
7	Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 231-242.	2.2	32
8	Long-Term Prognostic Value of Less-Stringent Electrocardiographic Q Waves and Fourth Universal Definition of Myocardial Infarction Q Waves. American Journal of Medicine, 2020, 133, 582-589.e7.	0.6	2
9	Incidence and predictors of atrial fibrillation episodes as detected by implantable loop recorder in patients at risk: From the LOOP study. American Heart Journal, 2020, 219, 117-127.	1.2	33
10	Incidence, Predictors, and Success of Ventricular Tachycardia Catheter Ablation in Arrhythmogenic Right Ventricular Cardiomyopathy (from the Nordic ARVC Registry). American Journal of Cardiology, 2020, 125, 803-811.	0.7	7
11	Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovascular Diabetology, 2020, 19, 156.	2.7	25
12	Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. American Heart Journal, 2020, 229, 61-69.	1.2	137
13	Comprehensive Evaluation of Rhythm Monitoring Strategies in Screening for Atrial Fibrillation. Circulation, 2020, 141, 1510-1522.	1.6	88
14	Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4078-4086.	1.8	25
15	Associations between common ECG abnormalities and out-of-hospital cardiac arrest. Open Heart, 2019, 6, e000905.	0.9	8
16	The relationship between serum potassium concentrations and electrocardiographic characteristics in 163,547 individuals from primary care. Journal of Electrocardiology, 2019, 57, 104-111.	0.4	10
17	Primary Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillator Therapy in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. American Journal of Cardiology, 2019, 123, 1156-1162.	0.7	10
18	Thyroid dysfunction and electrocardiographic changes in subjects without arrhythmias: a cross-sectional study of primary healthcare subjects from Copenhagen. BMJ Open, 2019, 9, e023854.	0.8	18

#	Article	IF	CITATIONS
19	Natural History of SubclinicalÂAtrialÂFibrillation Detected by Implanted LoopÂRecorders. Journal of the American College of Cardiology, 2019, 74, 2771-2781.	1.2	72
20	Visit-to-Visit Variability of Hemoglobin A1c in People Without Diabetes and Risk of Major Adverse Cardiovascular Events and All-Cause Mortality. Diabetes Care, 2019, 42, 134-141.	4.3	36
21	Heart transplantation in arrhythmogenic right ventricular cardiomyopathy â€" Experience from the Nordic ARVC Registry. International Journal of Cardiology, 2018, 250, 201-206.	0.8	25
22	Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care, 2018, 41, 258-266.	4.3	350
23	Rare truncating variants in the sarcomeric protein titin associate with familial and early-onset atrial fibrillation. Nature Communications, 2018, 9, 4316.	5.8	93
24	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline <scp>BMI</scp> or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes, Obesity and Metabolism, 2018, 20, 2210-2219.	2.2	87
25	Risk Prediction of Atrial Fibrillation Based on Electrocardiographic Interatrial Block. Journal of the American Heart Association, 2018, 7, .	1.6	32
26	Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. Nature Genetics, 2018, 50, 1234-1239.	9.4	547
27	Effect of onceâ€weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placeboâ€controlled, doubleâ€blind, crossover trial. Diabetes, Obesity and Metabolism, 2018, 20, 2565-2573.	2.2	16
28	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2017, 376, 890-892.	13.9	69
29	Electrocardiographic PR Interval Duration and Cardiovascular Risk: Results From the Copenhagen ECG Study. Canadian Journal of Cardiology, 2017, 33, 674-681.	0.8	29
30	Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. Clinical Pharmacokinetics, 2017, 56, 1391-1401.	1.6	34
31	Electrocardiographic Preexcitation and Risk of Cardiovascular Morbidity and Mortality. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	20
32	Complications after implantation of a new-generation insertable cardiac monitor: Results from the LOOP study. International Journal of Cardiology, 2017, 241, 229-234.	0.8	28
33	Atrial fibrillation detected by continuous electrocardiographic monitoring using implantable loop recorder to prevent stroke in individuals at risk (the LOOP study): Rationale and design of a large randomized controlled trial. American Heart Journal, 2017, 187, 122-132.	1.2	56
34	Association of Traditional Cardiovascular Risk Factors With Venous Thromboembolism. Circulation, 2017, 135, 7-16.	1.6	114
35	Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 Weeks in subjects with type 2 diabetes (SUSTAIN 3). Diabetes Research and Clinical Practice, 2016, 120, S51.	1.1	9
36	Reply to the Editor – Regarding the Role of Advanced Interatrial Block Pattern as a Predictor of Atrial Fibrillation. Heart Rhythm, 2016, 13, e87-e88.	0.3	0

#	Article	IF	Citations
37	Efficacy and Safety of Once-Weekly Semaglutide vs. Exenatide ER after 56 Weeks in Subjects with Type 2 Diabetes (SUSTAIN 3). Canadian Journal of Diabetes, 2016, 40, S41.	0.4	3
38	Association Between Heart Rate at Rest and Incident Atrial Fibrillation (from the Copenhagen) Tj ETQq0 0 0 rgB	T /Overlocl	k 19 Tf 50 70
39	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 1834-1844.	13.9	3,898
40	Electrocardiographic Tpeak–Tend interval and risk of cardiovascular morbidity and mortality: Results from the Copenhagen ECG study. Heart Rhythm, 2016, 13, 915-924.	0.3	34
41	The role of the sodium current complex in a nonreferred nationwide cohort of sudden infant death syndrome. Heart Rhythm, 2015, 12, 1241-1249.	0.3	26
42	Role of common and rare variants in <i>SCN10A</i> : results from the Brugada syndrome QRS locus gene discovery collaborative study. Cardiovascular Research, 2015, 106, 520-529.	1.8	108
43	Common and Rare Variants in SCN10A Modulate the Risk of Atrial Fibrillation. Circulation: Cardiovascular Genetics, 2015, 8, 64-73.	5.1	50
44	P-wave duration and the risk of atrial fibrillation: Results from the Copenhagen ECG Study. Heart Rhythm, 2015, 12, 1887-1895.	0.3	152
45	Next-generation sequencing of 34 genes in sudden unexplained death victims in forensics and in patients with channelopathic cardiac diseases. International Journal of Legal Medicine, 2015, 129, 793-800.	1.2	49
46	Common and Rare Variants in <i>SCN10A</i> Modulate the Risk of Atrial Fibrillation. Circulation: Cardiovascular Genetics, 2015, 8, 64-73.	5.1	59
47	Burden of Sudden Cardiac Death in Persons Aged $1\ \rm to\ 49\ Years$. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 205-211.	2.1	142
48	Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members. European Journal of Heart Failure, 2014, 16, 1337-1344.	2.9	200
49	Risk prediction of cardiovascular death based on the QTc interval: evaluating age and gender differences in a large primary care population. European Heart Journal, 2014, 35, 1335-1344.	1.0	98
50	Electrocardiographic Precordial STâ€Segment Deviations and the Risk of Cardiovascular Death: Results From the Copenhagen ECG Study. Journal of the American Heart Association, 2014, 3, e000549.	1.6	19
51	Left Anterior Fascicular Block and the Risk of Cardiovascular Outcomes. JAMA Internal Medicine, 2014, 174, 1001.	2.6	13
52	The diagnostic performance of imaging methods in ARVC using the 2010 Task Force criteria. European Heart Journal Cardiovascular Imaging, 2014, 15, 1219-1225.	0.5	70
53	Integrating Genetic, Transcriptional, and Functional Analyses to Identify 5 Novel Genes for Atrial Fibrillation. Circulation, 2014, 130, 1225-1235.	1.6	183
54	Sports-related sudden cardiac death in a competitive and a noncompetitive athlete population aged 12 to 49 years: Data from an unselected nationwide study in Denmark. Heart Rhythm, 2014, 11, 1673-1681.	0.3	111

#	Article	IF	CITATIONS
55	Risk of atrial fibrillation as a function of the electrocardiographic PR interval: Results from the Copenhagen ECG Study. Heart Rhythm, 2013, 10, 1249-1256.	0.3	110
56	New population-based exome data are questioning the pathogenicity of previously cardiomyopathy-associated genetic variants. European Journal of Human Genetics, 2013, 21, 918-928.	1.4	200
57	Epilepsy and risk of death and sudden unexpected death in the young: A nationwide study. Epilepsia, 2013, 54, 1613-1620.	2.6	127
58	Mutations in Genes Encoding Cardiac Ion Channels Previously Associated With Sudden Infant Death Syndrome (SIDS) Are Present With High Frequency in New Exome Data. Canadian Journal of Cardiology, 2013, 29, 1104-1109.	0.8	58
59	High prevalence of genetic variants previously associated with Brugada syndrome in new exome data. Clinical Genetics, 2013, 84, 489-495.	1.0	102
60	Genetic Modifier of the QTc Interval Associated With Early-Onset Atrial Fibrillation. Canadian Journal of Cardiology, 2013, 29, 1234-1240.	0.8	9
61	J-Shaped Association Between QTc Interval Duration and the Risk of Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 2557-2564.	1.2	112
62	A novel KCND3 gain-of-function mutation associated with early-onset of persistent lone atrial fibrillation. Cardiovascular Research, 2013, 98, 488-495.	1.8	104
63	Prior myocardial infarction in the young: predisposes to a high relative risk but low absolute risk of a sudden cardiac death. Europace, 2013, 15, 48-54.	0.7	8
64	The genetic component of Brugada syndrome. Frontiers in Physiology, 2013, 4, 179.	1.3	62
65	New Exome Data Question the Pathogenicity of Genetic Variants Previously Associated With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation: Cardiovascular Genetics, 2013, 6, 481-489.	5.1	74
66	Right bundle branch block: prevalence, risk factors, and outcome in the general population: results from the Copenhagen City Heart Study. European Heart Journal, 2013, 34, 138-146.	1.0	201
67	Cardiac symptoms before sudden cardiac death caused by coronary artery disease: a nationwide study among young Danish people. Heart, 2013, 99, 938-943.	1.2	25
68	High Prevalence of Long QT Syndrome–Associated <i>SCN5A</i> Variants in Patients With Early-Onset Lone Atrial Fibrillation. Circulation: Cardiovascular Genetics, 2012, 5, 450-459.	5.1	129
69	High prevalence of genetic variants previously associated with LQT syndrome in new exome data. European Journal of Human Genetics, 2012, 20, 905-908.	1.4	121
70	Low disease prevalence and inappropriate implantable cardioverter defibrillator shock rate in Brugada syndrome: a nationwide study. Europace, 2012, 14, 1025-1029.	0.7	27
71	Sodium Current and Potassium Transient Outward Current Genes in Brugada Syndrome: Screening and Bioinformatics. Canadian Journal of Cardiology, 2012, 28, 196-200.	0.8	22
72	Genetic Loci on Chromosomes 4q25, 7p31, and 12p12 Are Associated With Onset of Lone Atrial Fibrillation Before the Age of 40 Years. Canadian Journal of Cardiology, 2012, 28, 191-195.	0.8	50

#	Article	IF	CITATIONS
73	SCN1Bb R214Q found in 3 patients: 1 with Brugada syndrome and 2 with lone atrial fibrillation. Heart Rhythm, 2012, 9, 770-773.	0.3	61
74	Specificity of Elevated Intercostal Space ECG Recording for the Type 1 Brugada ECG Pattern. Annals of Noninvasive Electrocardiology, 2012, 17, 108-112.	0.5	24
75	Differences in investigations of sudden unexpected deaths in young people in a nationwide setting. International Journal of Legal Medicine, 2012, 126, 223-229.	1.2	10
76	Sudden unexpected death in infancy in Denmark. Scandinavian Cardiovascular Journal, 2011, 45, 14-20.	0.4	20
77	A Novel Nonsense Variant in Nav1.5 Cofactor MOG1 Eliminates Its Sodium Current Increasing Effect and May Increase the Risk of Arrhythmias. Canadian Journal of Cardiology, 2011, 27, 523.e17-523.e23.	0.8	45
78	Nationwide study of sudden cardiac death in persons aged 1–35 years. European Heart Journal, 2011, 32, 983-990.	1.0	303
79	Letter by Olesen et al Regarding Article, "MOG1: A New Susceptibility Gene for Brugada Syndrome― Circulation: Cardiovascular Genetics, 2011, 4, e22; author reply e23.	5.1	3
80	Common Polymorphisms in KNCJ5 Are Associated with Early-Onset Lone Atrial Fibrillation in Caucasians. Cardiology, 2011, 118, 116-120.	0.6	24
81	Incomplete right bundle branch block: a novel electrocardiographic marker for lone atrial fibrillation. Europace, 2011, 13, 182-187.	0.7	25
82	Screening of KCNN3 in patients with early-onset lone atrial fibrillation. Europace, 2011, 13, 963-967.	0.7	44
83	A nationwide, retrospective analysis of symptoms, comorbidities, medical care and autopsy findings in cases of fatal pulmonary embolism in younger patients. Journal of Thrombosis and Haemostasis, 2010, 8, 1723-1729.	1.9	14
84	Strategy for clinical evaluation and screening of sudden cardiac death relatives. Fundamental and Clinical Pharmacology, 2010, 24, 619-635.	1.0	18
85	Sick Sinus Syndrome, Progressive Cardiac Conduction Disease, Atrial Flutter and Ventricular Tachycardia Caused by a Novel <i>SCN5A</i> Mutation. Cardiology, 2010, 115, 311-316.	0.6	21
86	Incidence and etiology of sports-related sudden cardiac death in Denmarkâ€"Implications for preparticipation screening. Heart Rhythm, 2010, 7, 1365-1371.	0.3	193
87	Reply to the Editor—Incidence of Sports-Related Sudden Cardiac Death: The Danish Paradox. Heart Rhythm, 2010, 7, 1918-1919.	0.3	1
88	Risk Factors for Venous Thromboembolism. Circulation, 2010, 121, 1896-1903.	1.6	318